Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: Applicability to the practice of medicine in the United States

Mauricio G Cohen, J. J. Ferguson, R. A. Harrington, William W. Parmley

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Platelet-mediated thrombosis has been recognized as the primary pathophysiologic mechanism of acute coronary syndromes (ACS) and acute complications of percutaneous coronary intervention (PCI). Despite the clinical efficacy of the two most widely used antithrombotic agents, aspirin and heparin, each of them has significant therapeutic limitations. As a result, thrombosis and clinical events may occur despite the use of aspirin and heparin. The discovery that the platelet glycoprotein (GP) IIb-IIIa represents the final common pathway to platelet aggregation and the growing recognition of the key role of platelets in the progression of thrombosis prompted the development of several GP IIb-IIIa inhibitors as a potentially more effective form of antithrombotic therapy. Numerous trials of various GP IIb-IIIa inhibitors as adjuncts to PCI have strongly supported this hypothesis. The subject of this supplement is the review of more recent evaluations of GP IIb-IIIa inhibitors in the context of various treatment strategies for the management of patients with unstable angina or non-ST- segment elevation myocardial infarction, collectively known as non-ST-segment elevation ACS. Appropriate translation of these trials into clinical practice requires not only the knowledge of the trials' results but also the understanding of the design of individual studies, most notably the entry criteria and patient management strategies.

Original languageEnglish
JournalClinical Cardiology
Volume22
Issue number10 SUPPL. 6
StatePublished - Oct 1 1999
Externally publishedYes

Fingerprint

Platelet Glycoprotein GPIIb-IIIa Complex
Acute Coronary Syndrome
Medicine
Thrombosis
Percutaneous Coronary Intervention
Aspirin
Heparin
Blood Platelets
Integrin beta3
Fibrinolytic Agents
Unstable Angina
Platelet Aggregation
Therapeutics
Clinical Trials

Keywords

  • Acute coronary syndromes
  • Glycoprotein IIb-IIIa inhibitors
  • Myocardial infarction
  • Percutaneous coronary intervention
  • ST-segment and non-ST-segment acute coronary syndromes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes : Applicability to the practice of medicine in the United States. / Cohen, Mauricio G; Ferguson, J. J.; Harrington, R. A.; Parmley, William W.

In: Clinical Cardiology, Vol. 22, No. 10 SUPPL. 6, 01.10.1999.

Research output: Contribution to journalArticle

@article{9d487d7cadcf4208b000a5de149e53ff,
title = "Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: Applicability to the practice of medicine in the United States",
abstract = "Platelet-mediated thrombosis has been recognized as the primary pathophysiologic mechanism of acute coronary syndromes (ACS) and acute complications of percutaneous coronary intervention (PCI). Despite the clinical efficacy of the two most widely used antithrombotic agents, aspirin and heparin, each of them has significant therapeutic limitations. As a result, thrombosis and clinical events may occur despite the use of aspirin and heparin. The discovery that the platelet glycoprotein (GP) IIb-IIIa represents the final common pathway to platelet aggregation and the growing recognition of the key role of platelets in the progression of thrombosis prompted the development of several GP IIb-IIIa inhibitors as a potentially more effective form of antithrombotic therapy. Numerous trials of various GP IIb-IIIa inhibitors as adjuncts to PCI have strongly supported this hypothesis. The subject of this supplement is the review of more recent evaluations of GP IIb-IIIa inhibitors in the context of various treatment strategies for the management of patients with unstable angina or non-ST- segment elevation myocardial infarction, collectively known as non-ST-segment elevation ACS. Appropriate translation of these trials into clinical practice requires not only the knowledge of the trials' results but also the understanding of the design of individual studies, most notably the entry criteria and patient management strategies.",
keywords = "Acute coronary syndromes, Glycoprotein IIb-IIIa inhibitors, Myocardial infarction, Percutaneous coronary intervention, ST-segment and non-ST-segment acute coronary syndromes",
author = "Cohen, {Mauricio G} and Ferguson, {J. J.} and Harrington, {R. A.} and Parmley, {William W.}",
year = "1999",
month = "10",
day = "1",
language = "English",
volume = "22",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "10 SUPPL. 6",

}

TY - JOUR

T1 - Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes

T2 - Applicability to the practice of medicine in the United States

AU - Cohen, Mauricio G

AU - Ferguson, J. J.

AU - Harrington, R. A.

AU - Parmley, William W.

PY - 1999/10/1

Y1 - 1999/10/1

N2 - Platelet-mediated thrombosis has been recognized as the primary pathophysiologic mechanism of acute coronary syndromes (ACS) and acute complications of percutaneous coronary intervention (PCI). Despite the clinical efficacy of the two most widely used antithrombotic agents, aspirin and heparin, each of them has significant therapeutic limitations. As a result, thrombosis and clinical events may occur despite the use of aspirin and heparin. The discovery that the platelet glycoprotein (GP) IIb-IIIa represents the final common pathway to platelet aggregation and the growing recognition of the key role of platelets in the progression of thrombosis prompted the development of several GP IIb-IIIa inhibitors as a potentially more effective form of antithrombotic therapy. Numerous trials of various GP IIb-IIIa inhibitors as adjuncts to PCI have strongly supported this hypothesis. The subject of this supplement is the review of more recent evaluations of GP IIb-IIIa inhibitors in the context of various treatment strategies for the management of patients with unstable angina or non-ST- segment elevation myocardial infarction, collectively known as non-ST-segment elevation ACS. Appropriate translation of these trials into clinical practice requires not only the knowledge of the trials' results but also the understanding of the design of individual studies, most notably the entry criteria and patient management strategies.

AB - Platelet-mediated thrombosis has been recognized as the primary pathophysiologic mechanism of acute coronary syndromes (ACS) and acute complications of percutaneous coronary intervention (PCI). Despite the clinical efficacy of the two most widely used antithrombotic agents, aspirin and heparin, each of them has significant therapeutic limitations. As a result, thrombosis and clinical events may occur despite the use of aspirin and heparin. The discovery that the platelet glycoprotein (GP) IIb-IIIa represents the final common pathway to platelet aggregation and the growing recognition of the key role of platelets in the progression of thrombosis prompted the development of several GP IIb-IIIa inhibitors as a potentially more effective form of antithrombotic therapy. Numerous trials of various GP IIb-IIIa inhibitors as adjuncts to PCI have strongly supported this hypothesis. The subject of this supplement is the review of more recent evaluations of GP IIb-IIIa inhibitors in the context of various treatment strategies for the management of patients with unstable angina or non-ST- segment elevation myocardial infarction, collectively known as non-ST-segment elevation ACS. Appropriate translation of these trials into clinical practice requires not only the knowledge of the trials' results but also the understanding of the design of individual studies, most notably the entry criteria and patient management strategies.

KW - Acute coronary syndromes

KW - Glycoprotein IIb-IIIa inhibitors

KW - Myocardial infarction

KW - Percutaneous coronary intervention

KW - ST-segment and non-ST-segment acute coronary syndromes

UR - http://www.scopus.com/inward/record.url?scp=0032862058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032862058&partnerID=8YFLogxK

M3 - Article

C2 - 10526702

AN - SCOPUS:0032862058

VL - 22

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 10 SUPPL. 6

ER -